-Reuters Citing Interfax
Rallybio Announces Preliminary Results For RLYB212, An Anti-HPA-1a Monoclonal Antibody For The Prevention Of Fetal And Neonatal Alloimmune Thrombocytopenia
Rallybio Corporation (NASDAQ:RLYB) today announced positive preliminary results from its ongoing Phase 1b proof-of-concept study of RLYB212, an anti-HPA-1a monoclonal antibody for the prevention of fetal and neonatal